Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Immuneering has a consensus analyst rating of “Moderate Buy” from seven covered analysts, with an average 1-year price target of about $17.57.
• Recent research has been mixed but generally positive, including Needham raising its target to $18 and Cantor Fitzgerald initiating coverage with an overweight rating and a $17 target.
• The stock traded at $4.32, well below its 12-month high of $10.08, while the company also beat Q1 EPS estimates and is advancing its lead program IRX-2 in Phase 2 trials for painful diabetic peripheral neuropathy.

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $17.5714.

IMRX has been the subject of several recent research reports. Needham & Company LLC increased their price objective on Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a research report on Wednesday, June 24th. Chardan Capital reaffirmed a "buy" rating and set a $20.00 price target on shares of Immuneering in a research note on Tuesday, May 19th. Oppenheimer reaffirmed an "outperform" rating on shares of Immuneering in a research note on Monday, June 1st. Finally, Cantor Fitzgerald assumed coverage on Immuneering in a research note on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 price target for the company.

Immuneering Stock Performance

Immuneering stock opened at $4.32 on Friday. Immuneering has a twelve month low of $2.90 and a twelve month high of $10.08. The firm has a market cap of $279.50 million, a PE ratio of -3.69 and a beta of 0.41. The firm's 50 day moving average price is $4.75 and its two-hundred day moving average price is $5.05.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.09. Equities analysts anticipate that Immuneering will post -1.09 EPS for the current fiscal year.

Institutional Trading of Immuneering

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Immuneering by 2.0% in the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after purchasing an additional 4,458 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Immuneering during the fourth quarter valued at about $33,000. Southport Management L.L.C. lifted its position in shares of Immuneering by 1.8% in the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company's stock worth $1,826,000 after buying an additional 5,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company's stock worth $137,000 after buying an additional 6,196 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Immuneering by 30.0% during the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company's stock worth $192,000 after acquiring an additional 6,725 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.